{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "licensed-product", "type": "clause", "offset": [57, 73]}, {"key": "approved-by", "type": "definition", "offset": [83, 94]}, {"key": "regulatory-authority", "type": "definition", "offset": [97, 117]}], "snippet": "means the first disease condition for which a particular Licensed Product has been approved by a Regulatory Authority.", "samples": [{"hash": "hv9EgobeV11", "uri": "/contracts/hv9EgobeV11#first-indication", "label": "License Agreement (2seventy Bio, Inc.)", "score": 32.6878850103, "published": true}, {"hash": "8AZUJNO5AgM", "uri": "/contracts/8AZUJNO5AgM#first-indication", "label": "License Agreement (2seventy Bio, Inc.)", "score": 32.6878850103, "published": true}, {"hash": "5mXeKOSrLBn", "uri": "/contracts/5mXeKOSrLBn#first-indication", "label": "Co Development, Co Promote and Profit Share Agreement (2seventy Bio, Inc.)", "score": 32.6878850103, "published": true}], "size": 18, "hash": "e22ab3a2d266496a72cd5dd7be403316", "id": 1}, {"snippet_links": [], "snippet": "means [***].", "samples": [{"hash": "12GYeKoxaHv", "uri": "/contracts/12GYeKoxaHv#first-indication", "label": "Intellectual Property License Agreement (Eyegate Pharmaceuticals Inc)", "score": 29.7501711157, "published": true}, {"hash": "ikcg5NzSvZl", "uri": "/contracts/ikcg5NzSvZl#first-indication", "label": "Collaboration and License Agreement (Ultragenyx Pharmaceutical Inc.)", "score": 24.9753593429, "published": true}, {"hash": "99Fi1HHqITp", "uri": "/contracts/99Fi1HHqITp#first-indication", "label": "Collaboration and License Agreement (Ultragenyx Pharmaceutical Inc.)", "score": 24.8521560575, "published": true}], "size": 15, "hash": "42145ccc68badf480a8ed917c57dd5fc", "id": 2}, {"snippet_links": [{"key": "related-to", "type": "clause", "offset": [28, 38]}, {"key": "treatment-of", "type": "definition", "offset": [43, 55]}, {"key": "not-limited", "type": "clause", "offset": [96, 107]}, {"key": "signs-and", "type": "clause", "offset": [128, 137]}], "snippet": "means any Indication for or related to the treatment of Fragile X syndrome (FXS), including but not limited to the treatment of signs and symptoms of FXS and/or the treatment of any subpopulation or subset of FXS patients.", "samples": [{"hash": "hT0ILxO5Lky", "uri": "/contracts/hT0ILxO5Lky#first-indication", "label": "Merger Agreement (Harmony Biosciences Holdings, Inc.)", "score": 34.7002053388, "published": true}, {"hash": "hm8eKEuaPaI", "uri": "/contracts/hm8eKEuaPaI#first-indication", "label": "Contingent Value Rights Agreement (Harmony Biosciences Holdings, Inc.)", "score": 34.6536618754, "published": true}, {"hash": "ka0noAyxL8u", "uri": "/contracts/ka0noAyxL8u#first-indication", "label": "Merger Agreement (Zynerba Pharmaceuticals, Inc.)", "score": 34.6153319644, "published": true}], "size": 6, "hash": "21e5d10cb7fb07b059db261a58750bf1", "id": 3}, {"snippet_links": [{"key": "treatment-of", "type": "definition", "offset": [10, 22]}], "snippet": "means the treatment of Head and Neck (H&N) cancer in humans.", "samples": [{"hash": "gGOtbomzaQ4", "uri": "/contracts/gGOtbomzaQ4#first-indication", "label": "Assignment and License Agreement (GeoVax Labs, Inc.)", "score": 32.742642026, "published": true}, {"hash": "kCsFGH8MyXX", "uri": "http://pdf.secdatabase.com/1292/0001437749-21-026299.pdf", "label": "pdf.secdatabase.com", "score": 19.6661698422, "published": false}, {"hash": "atpHZQsE3FQ", "uri": "https://geovax.com/images/stories/uploads/Prosp_Supp_No._3_-_Reg_Stmt_333-239958_POA_-_11-12-21.pdf", "label": "geovax.com", "score": 10.9315537303, "published": false}], "size": 5, "hash": "1d5d95c2082f97dd78eb4465140bbb9b", "id": 4}, {"snippet_links": [{"key": "treatment-of", "type": "definition", "offset": [10, 22]}], "snippet": "means the treatment of Head and Neck (H&N) cancer in a human.", "samples": [{"hash": "gGOtbomzaQ4", "uri": "/contracts/gGOtbomzaQ4#first-indication", "label": "Assignment and License Agreement (GeoVax Labs, Inc.)", "score": 32.742642026, "published": true}, {"hash": "kCsFGH8MyXX", "uri": "http://pdf.secdatabase.com/1292/0001437749-21-026299.pdf", "label": "pdf.secdatabase.com", "score": 19.6661698422, "published": false}, {"hash": "atpHZQsE3FQ", "uri": "https://geovax.com/images/stories/uploads/Prosp_Supp_No._3_-_Reg_Stmt_333-239958_POA_-_11-12-21.pdf", "label": "geovax.com", "score": 10.9315537303, "published": false}], "size": 5, "hash": "440b5f43765fd181a38046c5a3467062", "id": 5}, {"snippet_links": [{"key": "section-72", "type": "clause", "offset": [29, 40]}], "snippet": "has the meaning set forth in Section 7.2.", "samples": [{"hash": "ef0TRgNaUbS", "uri": "/contracts/ef0TRgNaUbS#first-indication", "label": "Exclusive License Agreement (LAVA Therapeutics NV)", "score": 32.7446954141, "published": true}], "size": 5, "hash": "6020c8f278528ca94ed027c6e032c7ab", "id": 6}, {"snippet_links": [], "snippet": "means a first indication for which a Product receives approval.", "samples": [{"hash": "hOc38o1xSrk", "uri": "/contracts/hOc38o1xSrk#first-indication", "label": "Asset Purchase Agreement (Macrogenics Inc)", "score": 34.1991786448, "published": true}, {"hash": "2BlVTipMYym", "uri": "/contracts/2BlVTipMYym#first-indication", "label": "Asset Purchase Agreement (Provention Bio, Inc.)", "score": 29.4654346338, "published": true}, {"hash": "bqnSgdDMovV", "uri": "/contracts/bqnSgdDMovV#first-indication", "label": "Asset Purchase Agreement (Provention Bio, Inc.)", "score": 29.4435318275, "published": true}], "size": 4, "hash": "8cd71ce8c2e617ab1c74d5e070516f4a", "id": 7}, {"snippet_links": [], "snippet": "means Sickle Cell Disease.", "samples": [{"hash": "eo0HTI0yStB", "uri": "/contracts/eo0HTI0yStB#first-indication", "label": "License Agreement (Glycomimetics Inc)", "score": 24.8302532512, "published": true}, {"hash": "1hwyu6sxNlG", "uri": "/contracts/1hwyu6sxNlG#first-indication", "label": "License Agreement (Glycomimetics Inc)", "score": 24.7563312799, "published": true}, {"hash": "hxji8NCfMcx", "uri": "/contracts/hxji8NCfMcx#first-indication", "label": "License Agreement (Glycomimetics Inc)", "score": 24.6358658453, "published": true}], "size": 4, "hash": "2f0024250133ffd1607d431d71c58b12", "id": 8}, {"snippet_links": [{"key": "health-registration-approval", "type": "definition", "offset": [66, 94]}, {"key": "in-respect-of", "type": "clause", "offset": [95, 108]}, {"key": "the-product", "type": "clause", "offset": [109, 120]}, {"key": "combination-product", "type": "definition", "offset": [126, 145]}], "snippet": "means the first Indication in which AstraZeneca obtains the first Health Registration Approval in respect of the Product or a Combination Product.", "samples": [{"hash": "i2FbO365PaZ", "uri": "/contracts/i2FbO365PaZ#first-indication", "label": "Research Collaboration and License Agreement (Dynavax Technologies Corp)", "score": 22.8288843258, "published": true}, {"hash": "4CLWZHwqUZg", "uri": "/contracts/4CLWZHwqUZg#first-indication", "label": "Research Collaboration and License Agreement (Dynavax Technologies Corp)", "score": 20.0, "published": true}, {"hash": "5hPI9n8Ks35", "uri": "https://investors.dynavax.com/static-files/c5e8b7e6-2229-4bc2-b5c7-dfe2eb65318c", "label": "investors.dynavax.com", "score": 9.6570841889, "published": false}], "size": 4, "hash": "51f711e0787b925eaff11b9427d0071d", "id": 9}, {"snippet_links": [{"key": "indications-and-usage", "type": "definition", "offset": [46, 67]}, {"key": "regulatory-approval", "type": "clause", "offset": [104, 123]}, {"key": "the-product", "type": "clause", "offset": [128, 139]}, {"key": "regulatory-authority", "type": "definition", "offset": [145, 165]}, {"key": "not-limited", "type": "clause", "offset": [239, 250]}, {"key": "for-treatment", "type": "clause", "offset": [268, 281]}, {"key": "in-the-field", "type": "clause", "offset": [282, 294]}], "snippet": "means any indication listed under the header \u201cINDICATIONS AND USAGE\u201d of a Product\u2019s approved label upon Regulatory Approval for the Product by a Regulatory Authority, including any patient group, population or subpopulation, including but not limited to an indication for treatment in the Field.", "samples": [{"hash": "l5LSaNnCMh6", "uri": "/contracts/l5LSaNnCMh6#first-indication", "label": "License, Development, and Commercialization Agreement", "score": 31.340862423, "published": true}, {"hash": "eCSkbMXzK8w", "uri": "/contracts/eCSkbMXzK8w#first-indication", "label": "License, Development and Commercialization Agreement (Provention Bio, Inc.)", "score": 29.4435318275, "published": true}, {"hash": "eLimqmxB79F", "uri": "/contracts/eLimqmxB79F#first-indication", "label": "License, Development, and Commercialization Agreement (Provention Bio, Inc.)", "score": 29.3504449008, "published": true}], "size": 4, "hash": "77c1f086845eebe69208de8398a12848", "id": 10}], "next_curs": "Cl0SV2oVc35sYXdpbnNpZGVyY29udHJhY3RzcjkLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIZZmlyc3QtaW5kaWNhdGlvbiMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"title": "First Indication", "snippet": "means the first disease condition for which a particular Licensed Product has been approved by a Regulatory Authority.", "size": 155, "id": "first-indication", "examples": ["Clinical trial insurance obtained by GW Pharma for the conduct of clinical trials under the <strong>First Indication</strong> Development Plan shall include Otsuka as an additional named insured.", "If during the course to the <strong>First Indication</strong> Development Plan, either Party comes to believe that Development Costs for the <strong>First Indication</strong> are likely to exceed by ***% or more the estimated Development Costs, such Party shall notify the relevant JDC sub-committee at its next meeting, together with the reasons for the same.", "The Parties acknowledge and agree that it is their intent to seek Marketing Approval in the <strong>First Indication</strong> for a label that is as broad as reasonably possible (including, for clarity, broad use by age), taking into account, among other things, the requirements of Applicable Laws and the interest in making Licensed Products in the Field commercially available in a timely manner.", "In the case of a tied vote, Otsuka\u2019s vote shall control; provided, however, no action taken by virtue of Otsuka\u2019s controlling vote shall obligate GW Pharma to incur expenses or assume liabilities in addition to those contemplated by this Agreement, the <strong>First Indication</strong> Development Plan and the Second Indication Development Plan or to derogate from GW Pharma\u2019s right to manage and conduct the development activities under the <strong>First Indication</strong> Development Plan.", "Without limiting Aucela\u2019s rights to receive Milestone Payments pursuant to Section 6.2.1 for the <strong>First Indication</strong>, Otsuka shall pay to Acucela one-half (1/2) of the Milestone payments set forth in Section 6.2.1 above within sixty (60) days after the achievement of the corresponding development Milestone with respect to the Second Indication for which such development Milestones are achieved.", "At any time prior to [***] months before the [***], either Party may propose to Develop in the Profit Share Territory Licensed Products for one or more additional indications in the Field (i.e., in addition to the <strong>First Indication</strong>) by submitting to the JDC a written proposal for the Development thereof, including a proposed work plan, budget and timeline.", "A draft of the protocol including endpoints, to the extent they can be projected to the satisfaction of the Parties prior to March 1, 2005, for the <strong>First Indication</strong> shall be set forth in the Development Plan.", "The clinical trials that the Parties anticipate will be necessary to achieve regulatory approval of a Compound Product for the <strong>First Indication</strong> and a projection of the clinical trials that will be required for the Other Indications will be described in the Development Plan.", "Threshold expects to engage MediBIC or a third party to conduct all clinical trials for the <strong>First Indication</strong>.", "The JCC shall have authority, as set forth in this Section 3.7, to resolve only those disputes that relate to the content or performance of (i) any development plan including, but not limited to, the <strong>First Indication</strong> Development Plan and the Second Indication Development Plan and (ii) any commercialization plan including, but not limited to, the Commercialization Plan."], "related": [["second-indication", "Second Indication", "Second Indication"], ["initial-indication", "Initial Indication", "Initial Indication"], ["collaboration-product", "Collaboration Product", "Collaboration Product"], ["marketing-approval-application", "Marketing Approval Application", "Marketing Approval Application"], ["major-market-country", "Major Market Country", "Major Market Country"]], "related_snippets": [], "updated": "2025-07-07T00:17:00+00:00"}, "json": true, "cursor": ""}}